胺碘酮或利多卡因对比安慰剂治疗院外心脏骤停的贝叶斯分析
该研究对ALPS试验进行贝叶斯再分析,比较胺碘酮或利多卡因与安慰剂在难治性室颤/室速院外心脏骤停患者中的效果。结果显示胺碘酮改善生存和神经结局的概率较高,利多卡因获益较温和。
要点
- 胺碘酮改善生存概率83%-95%,利多卡因78%-90%
- 胺碘酮改善神经结局概率96%-99%,利多卡因88%-96%
- 胺碘酮估计生存改善2.9%,利多卡因1.7%(中等先验)
核心结论
- 在难治性室颤/室速院外心脏骤停患者中,胺碘酮治疗具有高概率改善生存和神经结局,利多卡因获益较温和。
研究设计与样本
- 对ALPS试验的贝叶斯再分析,纳入3026例成人院外心脏骤停患者,随机分为胺碘酮组974例、利多卡因组993例和安慰剂组1059例。
主要发现
- 胺碘酮组出院生存率24.4%,利多卡因组23.7%,安慰剂组21.0%。
- 胺碘酮改善生存的概率从83%(强先验)到95%(弱先验),利多卡因从78%(强先验)到90%(弱先验)。
- 胺碘酮估计生存改善2.9%(IQR 1.4%-3.8%),利多卡因1.7%(IQR 0.84%-3.2%)(中等先验)。
- 胺碘酮改善神经结局的概率从96%(弱先验)到99%(强先验),利多卡因从88%(弱先验)到96%(强先验)。
临床怎么用
- 对于难治性室颤/室速院外心脏骤停患者,胺碘酮可能带来较高的生存和神经功能改善概率,利多卡因的获益相对温和。
局限性
- 本研究为对ALPS试验的贝叶斯再分析,先验的强弱可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical trials for patients with shock-refractory out-of-hospital cardiac arrest (OHCA), including the Amiodarone, Lidocaine or Placebo (ALPS) trial, have been unable to demonstrate definitive benefit after treatment with antiarrhythmic drugs. A Bayesian approach, combining the available evidence, may yield additional insights. METHODS: We conducted a reanalysis of the ALPS trial comparing treatment with amiodarone or lidocaine with placebo in patients with OHCA following shock-refractory ventricular fibrillation or ventricular tachycardia (VF/VT). We used Bayesian regression to assess the probability of improved survival or improved neurological outcome on the 7-point modified Rankin Scale. We derived weak, moderate and strong priors from a previous clinical trial. RESULTS: The original ALPS trial randomised 3026 adult patients with OHCA to amiodarone (n=974, survival to hospital discharge 24.4%), lidocaine, (n=993, survival 23.7%) or placebo (n=1059, survival 21.0%). In our reanalysis the probability of improved survival from amiodarone ranged from 83% (strong prior) to 95% (weak prior) compared with placebo and from 78% (strong) to 90% (weak) for lidocaine-an estimated improvement in survival of 2.9% (IQR 1.4%-3.8%) for amiodarone and 1.7% (IQR 0.84%-3.2%) for lidocaine over placebo (moderate prior). The probability of improved neurological outcome from amiodarone ranged from 96% (weak) to 99% (strong) compared with placebo and from 88% (weak) to 96% (strong) for lidocaine. CONCLUSIONS: In a Bayesian reanalysis of patients with shock-resistant VF/VT OHCA, treatment with amiodarone had high probabilities of improved survival and neurological outcome, while treatment with lidocaine had a more modest benefit.
引用
- Lane DJ, Grunau B, Kudenchuk P, et al. Bayesian analysis of amiodarone or lidocaine versus placebo for out-of-hospital cardiac arrest. Heart. 2022. PMID: 35236764. doi:10.1136/heartjnl-2021-320513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。